Abbott Laboratories Stock News

Investing in excellent dividend stocks can be a great strategy to mitigate risk and boost long-term returns. Companies that can dispense regular payouts to their shareholders -- especially those that have done so for a long time -- generally have stable and steadily growing businesses that can perform relatively well even amid downturns.

A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal illness, as the companies face hundreds of lawsuits over the claims.

The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutes The test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025 ABBOTT PARK, Ill., and IRVINE, Calif.

Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.

Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.

Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -...

Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead Conduction System Pacing is an evolving technique specifical...